CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria

CARB-X is awarding Centauri Therapeutics of Sandwich, UK, up to $1.4 million in non-dilutive funding to develop a novel dual-acting immunotherapy to treat serious infections caused by Gram-negative pathogens, including drug-resistant strains of Enterobacteriaceae, P. aeruginosa, and A.baumannii.

“Centauri’s project is an exciting new approach to treating drug-resistant Gram-negative bacterial infections, and adds rich diversity to CARB-X’s early development portfolio of antibiotics, vaccines, rapid diagnostics and other life-saving products,” said Erin Duffy, Chief of Research and Development of CARB-X, which is based at Boston University School of Law in Boston USA.  “Projects in the Powered by CARB-X portfolio are in the early stages of development, but if successful, each offers tremendous hope and progress in the global fight against drug resistance. CARB-X is led by Boston University and funded by a global partnership.